New topical treatments for psoriasis

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 4, 2014, Pages 461-470

  Chiricozzi, Andrea ^a,b   Pitocco, Rossella ^a   Saraceno, Rosita ^a   Nistico, Steven Paul ^c   Giunta, Alessandro ^a   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

E6201; Pazopanib; Psoriasis; Tofacitinib; Topical therapy; WBI 1001

Indexed keywords

22 OXACALCITRIOL; [[5 (4 CYANOPHENOXY) 2,3 DIHYDRO 1 HYDROXY 2,1 BENZOXABOROLE]]; ALT 2074; AN 2728; ANTIPSORIASIS AGENT; BCT 194; BECOCALCIDIOL; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BIMOSIAMOSE; CALCIPOTRIOL; CALCITRIOL; CAPSAICIN; CLOBETASOL; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CRX 191; CT 327; E 6201; INDIRUBIN; JANUS KINASE INHIBITOR; LAS 41004; M 518101; MK 0873; MOMETASONE FUROATE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PAZOPANIB; PH 10; RUXOLITINIB; SALICYLIC ACID; SHP 141; SOMATOSTATIN; SPS 4251; STF 115469; SYI 2074; TACALCITOL; TACROLIMUS; TOFACITINIB; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WBI 1001;

ANTIINFLAMMATORY ACTIVITY; CREAM; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; NEUROGENIC INFLAMMATION; NONHUMAN; OINTMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; PSORIASIS;

EID: 84893651674     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.875159     Document Type: Review

References (74)

1. Schafer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology 2006;212:327-37
2. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005;5:699-711
3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73
4. Voorhees JJ. Pathophysiology of psoriasis. Annu Rev Med 1977;28:467-73
5. Barker JN, Karabin GD, Stoof TJ, et al. Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reaction. J Dermatol Sci 1991;2:106-11
6. Chiricozzi A, Zhang S, Dattola A, et al. Role of Th17 in the pathogenesis of cutaneous inflammatory diseases. J Biol Regul Homeost Agents 2012;26:313-18
7. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64:ii65-8; discussion ii69
8. Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol 2013;69:931-7
9. Gottlieb AB, Chaudhari U, Baker DG, et al. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physicians Global Assessment (PGA): a comparison. J Drugs Dermatol 2003;2:260-6
10. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol. Arch Dermatol 1989;125:1647-52
11. Reichrath J, Perez A, Muller SM, et al. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol 1997;77:268-72
12. O Neill JL, Feldman SR. Vitamin D analogue-based therapies for psoriasis. Drugs Today (Barc) 2010;46:351-60
13. Tanghetti EA. The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol 2009;8:s4-8
14. Feldman SR, Eastman WJ, Brundage T, et al. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. J Drugs Dermatol 2013;12:300-6
15. Available from: http://clinicaltrials.gov/ct2/results?term= calcipotriene+FOAM +0%2C005%25&Search=Search
16. Barker JN, Ashton RE, Marks R, et al. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999;141:274-8
17. Helfrich YR, Kang S, Hamilton TA, et al. Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study. Br J Dermatol 2007;157:369-74
18. Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol 2006;45:970-5
19. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54
20. Saraceno R, Gramiccia T, Frascione P, et al. Calcipotriene/betamethasone in the treatment of psoriasis: a review article. Expert Opin Pharmacother 2009;10:2357-65
21. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-5
22. Kragballe K, Austad J, Barnes L, et al. A 52 -week randomized safety study of calcipotriol/betamethasone dipropionate two compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155-60
23. Saraceno R, Camplone G, DAgostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat 2013. [Epub ahead of print]
24. Available from: http://clinicaltrials.gov/ct2/show/NCT01347255?term=LEO +90100+and+psoriasis&rank=1
25. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010;20:465-71
26. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 1999;38:16-24
27. Available from: http://clinicaltrials.gov/ct2/show/NCT01743118?term= SPS4251 +and+psoriasis&rank=1
28. Available from: http://clinicaltrials.gov/ct2/show/NCT00557739?term=CRx- 191 +and+psoriasis&rank=1
29. Available from: http://clinicaltrials.gov/ct2/show/NCT00796211?term=CRx- 197-002&rank=1
30. Available from: http://clinicaltrials.gov/ct2/show/NCT01610596? term=halobetasol+propionate+and +psoriasis&rank=3
31. Saraceno R, Kleyn CE, Terenghi G, Griffiths CE. The role of neuropeptides in psoriasis. Br J Dermatol 2006;155:876-82
32. Bernstein JE, Parish LC, Rapaport M, et al. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986;15:504-7
33. Weber G, Klughardt G, Neidhart M, et al. Treatment of psoriasis with somatostatin. Arch Dermatol Res 1982;272:31-6
34. Available from: http://www.creabilis-sa. com/ct-327/35. Available from: http://clinicaltrials.gov/ct2/show/NCT01465282?term=CT+327 +and+psoriasis& rank=2
35. Available from: http://www.centerwatch. com/news-online/article/3070/ creabilisbegins-phase-iib-trial-of-ct327-in-psoriasis
36. Nazarin R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 2009;10:1236-42
37. Available from: http://www.anacor.com 39. Available from: http://clinicaltrials.gov/show/NCT00132730
38. Available from: http://clinicaltrials.gov/ct2/results?term=MK-0873+AND +PSORIASIS&Search=Search
39. Cassano N, Vena GA. Janus kinase inhibition as a potential strategy for the treatment of psoriasis: state of the art and future perspectives. J Biol Regul Homeost Agents 2012;26:587-96
40. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol 2012;83:1136-45
41. Mak RK, Hundhausen C, Nestle FO, et al. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr 2009;100:2-13
42. Jabbari A, Jhonson-Huang LM, Krueger JG. Role of the immune system and immunological circuits in psoriasis. G Ital Dermatol Venereol 2011;146:17-30
43. Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013;169:137-45
44. Flagan ME, Blumenkopf TA, Brisette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-84
45. Available from: http://clinicaltrials.gov/ct2/show/NCT01831466?term=CP- 690% 2C550%2CPfizer+and+psoriasis&rank=13
46. Callis Duffin K, Luchi M, et al. Novel mechanism for topical treatment of plaque psoriasis -results of a randomized, double blind, concentration ranging, vehicle controlled 12 week study with JAK 1/2 inhibitor INCB018424 cream [abstract 261]. 2010 Annual Meeting of the Society for Investigative Dermatology, Hilton Atlanta, Atlanta, Georgia, May 5-8. J Invest Dermatol 2010;130:S44
47. Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012;67:658-64
48. Muramoto K, Goto M, Inoue Y, et al. E6201, a novel kinase inhibitor of mitogen-Activated protein kinase/extracellular signal-regulated kinase kinase -1 and mitogen-Activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther 2010;335:23-31
49. Available from: http://clinicaltrials.gov/ct2/show/NCT00539929? term=E6201&rank=2
50. Bissonnette R, Chen G, Bolduc C, et al. Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2 a, randomized, placebo-controlled clinical trial. Arch Dermatol 2010;146:446-9
51. Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol 2012;26:1516-21
52. Available from: http://clinicaltrials.gov/ct2/show/NCT00941278?term=PH-10 +and+psoriasis&rank=2
53. Available from: http://www.centerwatch. com/news-online/article/3092/ alerts.aspx 56. Available from: http://clinicaltrials.gov/ct2/show/NCT00823693? term=bimosiamose+AND+5+%25+cream +AND+psoriasi&rank=1
54. Bodenlenz M, Hofferer C, Magnes C, et al. Dermal PK/PD of a lipophilic topical drug in psoriatic patients by continuous intradermal membrane-free sampling. Eur J Pharm Biopharm 2012;81:635-41
55. Chang HN, Pang JH, Yang SH, et al. Inhibitory effect of indigo naturalis on tumor necrosis factor-Alpha-induced vascular cell adhesion molecule-1 expression in human umbilical vein endothelial cells. Molecules 2010;15:6423-35
56. Haider AS, Lowes MA, Suarez-Farinas M, et al. Identification of cellular pathways of Type1, Th17 cells, and TNF-And inducible nitril oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine a in psoriasis. J Immunol 2008;180:1913-20
57. Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face intertriginous areas in pediatrics patients. Pediatr Dermatol 2007;24:76-80
58. Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 2005;53:713-16
59. Bissonette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus of male genital psoriasis. J Cutan Med Surg 2008;12:230-4
60. Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003;48:564-8
61. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51:723-30
62. Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51:731-8
63. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59
64. Kreuter A, Sommer A, Hyun J, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% bethamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006;142:1138-43
65. Ahn SJ, Oh SH, Chang SE, et al. A case of infantile psoriasis with pseudoainhum successfully treated with topical pimecrolimus and low-dose narrowband UVB phototherapy. J Eur Acad Dermatol Venereol 2006;20:1332-4
66. Chiricozzi A, Chimenti S. Effective topical agents and emerging perspectives in the treatment of psoriasis. Expert Rev Dermatol 2012;7:283-93
67. Holick MF, Chimeh FN, Ray S. Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a randomized self-controlled trial an open trial. Br J Dermatol 2003;149:370-6
68. Available from: http://clinicaltrials.gov/ct2/show/NCT01873677?term= M518101 +and+psoriasis&rank=2
69. Boisseau-Garsaud AM, Donatien P, Margerin C, et al. EGF Receptor expression and growth of psoriatic and normal human keratinocytes are modulated by 1,25 (OH)2-vitamin D3 ex vivo. Arch Dermatol Res 1996;288:453-7
70. Kemeny L, Michel G, Arenberger P, Ruzicka T. Down-regulation of epidermal growth factor receptors by dithranol. Acta Derm Venereol 1993;73:37-40
71. Gilligan A, Bushmeyer S, Knowles BB. Variation in EGF-induced EGF receptor downregulation in human hepatomaderived cell lines expressing different amounts of EGF receptor. Exp Cell Res 1992;200:235-41
72. Nanney LB, Yates RA, King LE Jr. Modulation of epidermal growth factor in psoriatic lesions during treatment with topical EGF. J Invest Dermatol 1992;98:296-301
73. Roupe KM, Nybo M, Sjobring U, et al. Injury is a major inducer of epidermal innate responses during wound healing. J Invest Dermatol 2010;130:1167-77
74. Saraceno R, Chiricozzi A, Gabellini M, et al. Emerging applications of nanomedicine in dermatology. Skin Res Technol 2013;19:e13-19